公开(公告)号：US20140314839A1

公开(公告)日：2014-10-23

申请号：US14362040

申请日：2012-11-30

Applicant: BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA

Inventor： Joseph A. Vetro ,  Sam D. Sanderson

IPC: A61K9/48 ,  A61K39/00 ,  A61K38/08

CPC classification number: A61K9/48 ,  A61K9/0019 ,  A61K9/5031 ,  A61K38/08 ,  A61K38/1725 ,  A61K39/0005 ,  A61K2039/505 ,  C07K16/18 ,  C07K16/28 ,  C07K2317/34

Abstract: Controlled-release formulations of carboxy-terminal C5a analogs (such as sustained-release formulations of the analogs), and their use in methods for treating and preventing an infection or a disease such as cancer, for directly killing microorganisms, for vaccine preparation, for inducing an immune response and for targeting antigen-presenting cells and other cells bearing a C5a receptor, are provided.

Abstract translation: 羧基末端C5a类似物（例如类似物的缓释制剂）的控制释放制剂及其在治疗和预防感染或疾病如癌症的方法中的用途，用于直接杀死微生物，用于疫苗制备，用于疫苗制备 诱导免疫应答并靶向抗原呈递细胞和其它具有C5a受体的细胞。

公开(公告)号：US10363282B2

公开(公告)日：2019-07-30

申请号：US15869396

申请日：2018-01-12

Applicant: Board of Regents of The University of Nebraska ,  San Diego State University Research Foundation

Inventor： Sam D. Sanderson ,  Joy Arlene Phillips ,  Edward Leroy Morgan ,  Marilyn Louise Thoman ,  Tamsin Sheen ,  Kelly S. Doran ,  Elizabeth Louise Virts ,  Tammy Kielian ,  Mark Hanke

IPC: A61K38/08 ,  A61K38/10 ,  A61K45/06

Abstract: Materials and methods for treating an infection or disease, activating an immune cell at a site of infection or disease, and for directly killing microorganisms, using response-selective carboxy-terminal C5a analogs, are provided.

公开(公告)号：US20180140659A1

公开(公告)日：2018-05-24

申请号：US15869396

申请日：2018-01-12

Applicant: Board of Regents of The University of Nebraska ,  San Diego State University Research Foundation

Inventor： Sam D. Sanderson ,  Joy Arlene Phillips ,  Edward Leroy Morgan ,  Marilyn Louise Thoman ,  Tamsin Sheen ,  Kelly S. Doran ,  Elizabeth Louise Virts ,  Tammy Kielian ,  Mark Hanke

IPC: A61K38/08 ,  A61K45/06 ,  A61K38/10

CPC classification number: A61K38/08 ,  A61K38/10 ,  A61K45/06 ,  Y02A50/463 ,  Y02A50/473

Abstract: Materials and methods for treating an infection or disease, activating an immune cell at a site of infection or disease, and for directly killing microorganisms, using response-selective carboxy-terminal C5a analogs, are provided.

公开(公告)号：US20150218516A1

公开(公告)日：2015-08-06

申请号：US14642085

申请日：2015-03-09

Applicant: The Board of Regents of the University of Nebraska

Inventor： Stefano R. Tarantolo ,  Anthony A. Floreani ,  Ralph J. Hauke ,  John D. Jackson ,  Sam D. Sanderson ,  Art J. Heires ,  Sandra Gunselman

IPC: C12N5/0783 ,  A61K39/00

CPC classification number: C12N5/0638 ,  A61K38/00 ,  A61K39/0011 ,  A61K39/12 ,  A61K39/292 ,  A61K39/385 ,  A61K2035/124 ,  A61K2039/5154 ,  A61K2039/5158 ,  A61K2039/545 ,  A61K2039/55522 ,  A61K2039/55533 ,  A61K2039/572 ,  A61K2039/6031 ,  A61K2039/627 ,  C07K14/472 ,  C07K14/57 ,  C07K16/18 ,  C07K16/2869 ,  C07K2317/34 ,  C07K2319/00 ,  C12N2501/998 ,  C12N2502/1121 ,  C12N2730/10134

Abstract: Molecular adjuvants are disclosed comprising an antigen presenting cell-targeting ligand linked to an immunogen, e.g. tumor associated antigens, bacterial or viral antigens. The ligand and the immunogen are linked via a cleavable linker such as a protease-sensitive oligopeptide, to facilitate processing of the adjuvant by the antigen presenting cell. Methods are disclosed for delivery of these molecular adjuvants to patients, resulting in the transduction of activating signals to the targeted antigen presenting cell, thereby enhancing the immune response to the co-delivered immunogen.

Abstract translation: 公开了分子佐剂，其包含与免疫原连接的抗原呈递细胞靶向配体，例如 肿瘤相关抗原，细菌或病毒抗原。 配体和免疫原通过可切割接头如蛋白酶敏感性寡肽连接，以促进抗原呈递细胞对佐剂的加工。 公开了将这些分子佐剂递送给患者的方法，导致将活化信号转导至靶向抗原呈递细胞，从而增强对共同递送的免疫原的免疫应答。

公开(公告)号：US20190083408A1

公开(公告)日：2019-03-21

申请号：US16209300

申请日：2018-12-04

Applicant: BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA

Inventor： Joseph A. Vetro ,  Sam D. Sanderson

IPC: A61K9/48 ,  C07K16/28 ,  C07K16/18 ,  A61K38/08 ,  A61K39/00 ,  A61K38/17 ,  A61K9/50 ,  A61K9/00

Abstract: Controlled-release formulations of carboxy-terminal C5a analogs (such as sustained-release formulations of the analogs), and their use in methods for treating and preventing an infection or a disease such as cancer, for directly killing microorganisms, for vaccine preparation, for inducing an immune response and for targeting antigen-presenting cells and other cells bearing a C5a receptor, are provided.

公开(公告)号：US10945962B2

公开(公告)日：2021-03-16

申请号：US16209300

申请日：2018-12-04

Applicant: BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA

Inventor： Joseph A. Vetro ,  Sam D. Sanderson

IPC: A61K9/46 ,  A61K38/08 ,  C07K16/18 ,  A61K9/48 ,  A61K38/17 ,  A61K39/00 ,  C07K16/28 ,  A61K9/00 ,  A61K9/50

Abstract: Controlled-release formulations of carboxy-terminal C5a analogs (such as sustained-release formulations of the analogs), and their use in methods for treating and preventing an infection or a disease such as cancer, for directly killing microorganisms, for vaccine preparation, for inducing an immune response and for targeting antigen-presenting cells and other cells bearing a C5a receptor, are provided.

公开(公告)号：US20200172587A1

公开(公告)日：2020-06-04

申请号：US16621797

申请日：2018-06-12

Applicant: Board of Regents of the University of Nebraska ,  San Diego State University Research Foundation

Inventor： Sam D. Sanderson ,  Edward Leroy Morgan

IPC: C07K14/47 ,  A61K38/17 ,  A61P35/00 ,  A61K9/00 ,  A61P37/04

Abstract: Hydrochloride salt forms of synthetic C-terminal peptide analogs of C5a, which are response selective agonists of C5aR-bearing antigen presenting cells. Methods of inducing an immune response in a subject by administering such peptide analogs alone or in combination with other active agents are also disclosed.

公开(公告)号：US10220002B2

公开(公告)日：2019-03-05

申请号：US14362040

申请日：2012-11-30

Applicant: BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA

Inventor： Joseph A. Vetro ,  Sam D. Sanderson

IPC: A61K9/48 ,  A61K38/17 ,  A61K39/00 ,  A61K38/08 ,  C07K16/18 ,  C07K16/28 ,  A61K9/00 ,  A61K9/50

Abstract: Controlled-release formulations of carboxy-terminal C5a analogs (such as sustained-release formulations of the analogs), and their use in methods for treating and preventing an infection or a disease such as cancer, for directly killing microorganisms, for vaccine preparation, for inducing an immune response and for targeting antigen-presenting cells and other cells bearing a C5a receptor, are provided.

公开(公告)号：US20180066018A1

公开(公告)日：2018-03-08

申请号：US15556949

申请日：2016-03-11

Applicant: Board Of Regents Of The University Of Nebraska

Inventor： Sam D. Sanderson ,  Jonathan Vennerstrom

IPC: C07K7/06 ,  A61K9/48 ,  A61K38/17

CPC classification number: C07K7/06 ,  A61K9/0019 ,  A61K9/107 ,  A61K9/48 ,  A61K38/00 ,  A61K38/1745 ,  A61K39/39 ,  A61K2039/55516 ,  C07K7/00

Abstract: Conformationally-stable peptide analogs of the response selective C5a agonist EP67 having the formula Tyr-Ser-Phe-Lys-Asp-Met-Xaa-(Xaa2)-(D-Ala)-Arg (SEQ ID NO:1), wherein Xaa is a modified proline residue or a residue substitution for proline, and Xaa2 is leucine or N-methyl leucine. The conformationally-stable peptides selectively bind and activate APCs without directly engaging/binding C5a receptor-bearing cells involved in pro-inflammatory activities of natural C5a. Compositions and methods of using the peptide analogs are also described.